Health Panel Hold‑Up Slows New Cancer Screening Rules

The U.S. Health Secretary has paused the preventive‑care panel that sets which free medical tests health plans must cover. Experts warn this delay is pushing back critical updates to cancer screening guidelines.

What the Panel Does

• Established in 1984, it recommends routine tests—such as cancer and heart disease screenings—for inclusion at no cost in health plans.
• When it stops making recommendations, insurers can decide independently whether to add those services.

Current Status

• No meeting in over a year.
• Three scheduled sessions have been canceled, and five members who finished their terms in December remain unfilled.
• Without fresh experts, the panel cannot review or update guidance.

Why It Matters

Early detection saves lives and money, but upfront costs of tests like mammograms can reach $7,000 over a lifetime for an average‑risk woman.

• Normally the panel releases about 22 sets of recommendations annually.
• Last year only seven drafts were posted; none this year.

Political Response

Senators have urged the Health Secretary to support the panel, citing fears that a weakened task force could erode evidence‑based care.
The pause aligns with a broader agenda to cut federal health regulation and reduce required benefits under the Affordable Care Act.

Potential Consequences

• Insurance plans may omit essential screenings and preventive drugs.
• Patients could face higher out‑of‑pocket costs for newer HIV prevention shots, while updates on prostate cancer screening and vitamin D use remain stalled.